Taysha Gene Therapies (TSHA) PT Raised to $67.50 at Chardan Capital Markets

April 12, 2021 12:15 PM EDT
Get Alerts TSHA Hot Sheet
Price: $22.20 +6.02%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 9 | New: 59
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Chardan Capital Markets analyst Gbola Amusa raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $67.50 (from $60.00) while maintaining a Buy rating.

The analyst commented, "This morning, Taysha Gene Therapies (Buy) announced the acquisition of exclusive worldwide rights to AAV9-based gene therapy (GT) TSHA-120 for giant axonal neuropathy (GAN), potentially transforming Taysha into a pivotal-stage GT company. The TSHA-120 program was invented in the lab of Dr. Steven Gray, Taysha's Chief Scientific Advisor, at UT Southwestern. The ongoing NIH-run TSHA-120 non-randomized, escalating dose phase I trial is also notable for being the first intrathecally dosed gene therapy program in history. TSHA-120 has received FDA Pediatric Disease and Orphan Drug designations, and with an estimated 2,400 patients in the US and Europe, the program could represent a near-term commercial opportunity of >$2 bn, thus meriting Taysha's focus from here on building commercial capabilities."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Chardan Capital Markets, Definitive Agreement, Gbola Amusa, FDA